Abstract
Radioligand therapy with 177Lu-PSMA-617 is an innovative and effective therapy for castrate-resistant metastatic prostate cancer patients. For patients with symptomatic bone metastases without visceral metastases, the guidelines recommend radionuclide therapy with 223Ra-dichloride as a single therapeutic agent or in combination with hormone therapy. The aim of this study was to evaluate the safety of repeated cycles of 177Lu-PSMA-617 after exposure to more cycles of 223Ra. Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with 223Ra. Group 1 included 20 patients, who had received therapy with 223Ra prior to Lu-PSMA-617 therapy. Group 2, which was the control group regarding hematotoxicity, comprised 29 patients without any history of a bone-targeted radionuclide therapy. No CTC 4° hematotoxicity was observed in the entire study population. There was no CTC 3° or CTC 4° leucopenia in either group. One and three patients from group 1 and 2, respectively, showed CTC 3° anemia. In group 1 there was significantly more CTC 2° anemia (50% vs. 6.9%) (p=0.008). One patient from group 1 (5%) showed a CTC 3° thrombocytopenia without any concurrent anemia, and two patients from group 2 (7%) showed a CTC 3° thrombocytopenia, one with CTC 3° anemia and one without any anemia. There were no significant differences between the two groups regarding leucopenia and thrombocytopenia. These results confirmed that performing repeated cycles of Lu-PSMA-617 after 223Ra seems to be safe with a very small probability of hematotoxicity.
Highlights
Prostate-specific membrane antigen (PSMA) is an attractive target for the diagnosis and therapy of metastasized prostate cancer [1,2,3,4]
Forty-nine patients were treated with three cycles of Lu-PSMA-617 divided into two groups subjected to a history of therapy with 223Ra
No CTC 4° hematotoxicity was observed in the entire study population
Summary
Prostate-specific membrane antigen (PSMA) is an attractive target for the diagnosis and therapy of metastasized prostate cancer (mPC) [1,2,3,4]. All of the published papers about radioligand therapy (RLT) with 177Lu-PSMA-617 (Lu-PSMA-617) have demonstrated that this therapy is safe and has a low toxicity profile [5,6,7,8]. According to our recently published results, performing Lu-PSMA-617 therapy after therapy with 223Ra seems safe with a low hematotoxicity profile [5, 7, 10, 11], because of the limited number of patients in these studies, as well as the low number of performed therapy cycles 2 www.impactjournals.com/oncotarget cycles), there was a need to evaluate hematotoxicity in patients after exposure to 223Ra who received 3 cycles of RLT compared to patients without a history of therapy with 223Ra According to our recently published results, performing Lu-PSMA-617 therapy after therapy with 223Ra seems safe with a low hematotoxicity profile [5, 7, 10, 11], because of the limited number of patients in these studies, as well as the low number of performed therapy cycles (max. 2 www.impactjournals.com/oncotarget cycles), there was a need to evaluate hematotoxicity in patients after exposure to 223Ra who received 3 cycles of RLT compared to patients without a history of therapy with 223Ra
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
